Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for...

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s multi-center Phase 1-2 clinical trial of IMPT-314 in...

MMRGlobal to Form Wholly-Owned Subsidiary to Maximize Value of Biotech Assets LOS ANGELES, CA--(Marketwire - March 8, 2011) -  MMRGlobal, Inc. (OTCBB: MMRF) today announced that it has begun the process of forming a wholly-owned subsidiary called MMR Life Sciences Group,...

MMRGlobal Prevails in Biotech Assets Case With Lymphoma Research Foundation LOS ANGELES, CA--(Marketwire - September 24, 2010) -  MMRGlobal, Inc. (OTCBB: MMRF) (MMR) announced today that it has successfully opposed a Summary Judgment Motion brought by the Lymphoma...